HPV vaccination in the context of upcoming shifts in Gavi's grant model

Emily Kobayashi

Head, HPV Vaccine Programme

CHIC Symposium

October 1, 2025

gavi.org

Purpose of this talk:

To describe how Gavi's grant model is changing

and reflect on how we can successfully support HPV vaccine programmes in this new context.

But first, what stays the same: The Gavi 6.0 strategy affirms continued support to leaving no one behind with immunisation

VISION

Leaving no one behind with immunisation

MISSION

To **save lives** and **protect people's health** by increasing **equitable and sustainable use of vaccines**

PRINCIPLES

- Country-led, sustainable
- Community-owned, inclusive
- Zero-dose and missed communities, first priority
- Gender-focused
- Differentiated, fragile-responsive
- Integrated
- Adaptive, resilient
- Climate-sensitive
- Innovative
- Collaborative, accountable

GOALS

1. **INTRODUCE AND SCALE UP VACCINES**
2. **STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION**
3. **IMPROVE PROGRAMMATIC AND FINANCIAL SUSTAINABILITY OF IMMUNISATION PROGRAMMES**
4. **ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS**

ENABLERS

- Long-term predictable funding
- One Alliance
- Global political commitment
- Simple, efficient and agile Gavi operating model
- Digitalisation, improved data and evidence
- Collaboration with private sector and development finance institutions

Gavi Leap

Transforming through simplicity, transparency and synergy

- Changes are required to **roll out 6.0**
- Enables **reform of Gavi in a new era**
- Principles are a blueprint for a **wider global health leap**
  - Country centricity
  - Country sovereignty
  - Focused mandates
  - Finite lifespans

Key change: Consolidation of many funding levers to two, end of special HPV levers

In-kind Cash to country

Previous levers

- Vaccine support
- Diagnostics
- Health system strengthening (HSS)
- Equity Accelerator Fund (zero-dose)
- Cold Chain Equipment Optimisation Platform (CCEOP)
- Targeted Country Assistance (TCA)
- Vaccine Introduction Grants (VIG)
- Operational support for measles/measles-rubella follow-up vaccination campaigns
- Switch grants
- Innovation top-up
- Other vaccination campaign operational support (to be allocated outside of country ceiling)

New levers

Vaccines & diagnostics
In-kind vaccine support and diagnostics

Cash to countries
Consolidated cash envelope to countries

CSO funding requirement: Board mandate to allocate >10% funding to civil society partners

Minimum floor based on Alliance forecast of **cold chain equipment** needs

Guardrail for **measles/measles-rubella follow-up vaccination campaigns**

Key change: Transition into the consolidated grant cycle

A. Single holistic application *(60% of countries)*

Sample transition



B. Reprogramming and funding lever consolidation *(40% of countries)*

Sample transition



Introduction of ‘use it or lose it’ principle for country funding allocation is critical to sustain grant cycle alignment

Example: what funding lever consolidation & grant cycle alignment looks like in practice



Other key changes in Gavi support impacting HPV vaccine programme costs and sustainability

- **Overall decrease** in resources available
- Potential introduction of **country vaccine budgets**
- **Co-financing policy changes**, indicating need to select an optimized portfolio:
  - ***Initial Self-Financing countries*: ** 4% of vaccine costs for HPV rather than $0.20 per dose
  - ***Multi-age cohort campaign cofinancing*** newly required
  - ***Revised eligibility*** for some countries
  - Final cofinancing policy for 2026 has been shared from Gavi to Ministries of Health and Finance:

Product	Price per dose	ISF cofinancing amount per dose (indicative)
Cervarix (GSK)	$5.18	$0.21
Gardasil-4 (Merck)	$4.50	$0.18
Cecolin (Innovax)	$2.90	$0.12
Walrinvax (Walvax)*	$2.80	$0.11

Adobe Acrobat Document

* Walrinvax requires a 2-dose schedule

Gavi The Vaccine Alliance

How can we support sustained HPV vaccination programs in the Gavi 6.0 context?

Recommendation 1:

Plan for sustained HPV vaccine delivery in the context of holistic EPI planning and funding

Recommendation 2:

Look for opportunities to integrate HPV vaccines with other services for school-age children

Recommendation 3:

Consider opportunities to optimize vaccine portfolio, including for HPV

Asanteni Sana